Interview: Prof. Dr. Murat Özgören – Vice-Rector, Dokuz Eylül…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Dokuz Eylül Health Technopark DEPARK
The first thematic health technopark in Turkey that is fully integrated with hospital, research centers and medical schools. It is an ideal location for biotech and medical device companies inb Turkey for R&D, product development and soft-landing. DEPARK has started medical technopark services at its mother building ZEYTIN. The name zeytin refers to olives and it stands for 3500 years lifespan of olive trees while still producing olives. It also refers to natural health remedies that are attached to the olive (e.g. as in the movie Lorenzo’s Oil). There is a specifically medicine oriented technology transfer office called DETTO (Dokuz Eylül Technology Transfer Office). It has a wide variety of services from international soft landing, tax and law support, IP rights management, incubation, technical consultancy, funding, clinical trials, pre-clinical consultation to marketing and guidance for international partnering. The hosting university, Dokuz Eylül University, has 14 faculties (app 67,000 students) to support the larger ecosystem for a wide range of activities and research. The ecosystem includes a university hospital over 1,100 beds, medical school, medical graduate study programs, medical research institutes (ie oncology, genome etc), nearly 1,000 academics, health technologies accelerator, associate service study programs like nursing, health technicians, sports technologies, physiotherapy center, medical devices calibration center and home-care research center.
BioIzmir
BioIzmir is an international gateway project for creating a one-stop-shop ecosystem for biotech and medical devices. It is located within a health technopark (DEPARK) embedded into a hospital complex.
From design to manufacturing, process to IPR rights this will be a critical partner for companies and development/tech transfer organizations. Izmir Health Technologies Development and Accelerator Center will serve as a hub of the essential elements known in medical circle as “from the laboratory bench to the patient’s bedside”. The structure of the Center will provide “one-stop-shop” aimed to establish Izmir as the intersection of health enterprise and innovation in regional, national and international contexts. The activities within the scope of the project will create an eco system in which integration occurs between the industry and the dynamics of R&D and innovation.
iBG-izmir
Dokuz Eylul University Izmir Biomedicine and Genome Center (iBG-izmir) is developed within “Bioİzmir” Science and Technology Park, which is the result of the innovative partnership of DEU Health Campus, the Faculty of Medicine & University Hospital and the Health Themed Technopark (DEPARK). iBG is the first such regional hub, with headquarters in Izmir, Turkey’s third largest city and a critical locomotive for growing Turkish economy, particularly within the health sector. iBG’s vision is to establish a most prominent center for health and life sicences in South-West Europe and MENA countries in a 10 years period. This comprehensive regional hub will be multidisciplinary in approach and shall bring molecular biology, genetics, medicine, pharmaceutical sciences, bioengineering, computer engineering and many other fields together. iBG-izmir will open its doors in 09-10 Sep 2015 with including Nobel session and reception.
Contact
Dokuz Eylül Üniversitesi İnciraltı Yerleşkesi Balçova
35340 İzmir Türkiye
Tel: +90 (232) 412 80 00
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Omega CRO was the first clinical trial company in Turkey. A few years later, in 2002, we saw a sharp increase of similar businesses, including Quintiles. What spurred the establishment…
Currently, what are the main priorities and goals of ISPAT related to the Healthcare and Pharmaceuticals sector, and what are the overall strategies designed to achieve these objectives? As an…
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Can you describe the current investment climate in Turkey for pharma companies? Turkey’s economic and political situation are very important factors to consider for foreign investors. Over the last three…
Mr. Ediz Günsel, could you introduce yourself to our readers ? Yes; I have been with the firm over twenty years, including 5 years with PwC London. In my twenty…
At Reckitt Benckiser, you have gradually taken positions of increasing responsibility over the last decade in Marketing. What would you highlight as the main specificities of Turkish market compared to…
Poland and Turkey present many similarities, in terms of market size and frequency of reforms for instance, but also a lot of differences, as the generic penetration is much lower…
The company entered the Turkish market in 2005, and made important product launches in 2008. You have been General Manager of Ferring Turkey over those last 7 years. Can you…
Would you like to come back for our readers on the main milestones in Daiichi Sankyo’s development over the past few years in Turkey and how it positions itself in…
You have pharmaceuticals production in your background and have recently joined PharmaVision as General Manager. To what extent does this speak about the company’s direction? Could you elaborate on your…
Mr Fadıllıoğlu, after a previous position at Abbott, you were recently appointed head of GSK Turkey. How different is GSK as an organization? What new therapeutic areas, processes, or corporate…
Mr Acar, could you present to our readers the Institution’s historical development and its role today in the Turkish pharmaceutical and healthcare sector? Before Social Security Reform was initiated, there…
See our Cookie Privacy Policy Here
